Polaris Pharmaceuticals
Mariusz Stempniak has a strong background in pharmaceutical and biotherapeutics research. Mariusz started their career at Pfizer in 1994 as a Principal Scientist and remained in this role until 2010. Mariusz then moved on to Multimeric Biotherapeutics, Inc., where they served as a Principal Scientist until 2013. Currently, they are employed as a Senior Scientist at Polaris Pharmaceuticals where they continue to contribute their expertise in scientific research.
Mariusz Stempniak holds a PhD in Biology from the University of A. Mickiewicz in Poznan, Poland. No specific start or end years were provided for this educational experience.
Polaris Pharmaceuticals
Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans. Polaris' lead project is ADI-PEG 20, a biotherapeutic agent that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma. Polaris is collaborating with EnzymeRx in the development of Uricase-PEG 20 for the treatment of gout, tumor lysis syndrome, and other diseases related to hyperuricemia. Polaris is also researching and developing other biotherapeutic agents and has a small molecule drug program. The latter utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.